Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 22fludarabine phosphate 18Busulfan 16Antilymphocyte Serum 15Radiotherapy 12Cyclosporine 11Cord Blood Stem Cell Transplantation 11Peripheral Blood Stem Cell Transplantation 10Melphalan 10Filgrastim 10Tacrolimus 9Mycophenolic Acid 9Methylprednisolone 9Methotrexate 9Etoposide 7Cytarabine 7Whole-Body Irradiation 6sargramostim 4Tretinoin 3Thalidomide 3Carboplatin 3venetoclax 2ruxolitinib 2Thiotepa 2Thioguanine 2Specimen Handling 2Sirolimus 2Rituximab 2Leucovorin 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × romidepsin × Classical hematology × Clear all
NCT00042822 2011-05-17

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡